Randomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrence

Simple item page
dc.contributor.authorKruis, W.
dc.contributor.authorKardalinos, V.
dc.contributor.authorEisenbach, T.
dc.contributor.authorLukas, M.
dc.contributor.authorVich, T.
dc.contributor.authorBunganic, I.
dc.contributor.authorPokrotnieks, Juris
dc.contributor.authorDerova, J.
dc.contributor.authorKondrackiene, J.
dc.contributor.authorSafadi, R.
dc.contributor.authorTuculanu, D.
dc.contributor.authorTulassay, Z.
dc.contributor.authorBanai, J.
dc.contributor.authorCurtin, A.
dc.contributor.authorDorofeyev, A. E.
dc.contributor.authorZakko, S. F.
dc.contributor.authorFerreira, N.
dc.contributor.authorBjörck, S.
dc.contributor.authorDiez Alonso, M. M.
dc.contributor.authorMäkelä, J.
dc.contributor.authorTalley, N. J.
dc.contributor.authorDilger, K.
dc.contributor.authorGreinwald, R.
dc.contributor.authorMohrbacher, R.
dc.contributor.authorSpiller, R.
dc.date.accessioned2021-12-13T14:25:01Z
dc.date.available2021-12-13T14:25:01Z
dc.date.issued2017-08
dc.descriptionPublisher Copyright: © 2017 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd
dc.description.abstractBackground: Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. Aim: To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. Methods: Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left-sided diverticulitis. Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG-51, n=330). The primary endpoint was the proportion of recurrence-free patients during 48 weeks (SAG-37 and SAG-51) or 96 weeks (SAG-51) of treatment. Results: Mesalazine did not increase the proportion of recurrence-free patients over 48 or 96 weeks compared to placebo. In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo (P=.226). In SAG-51, the proportion of recurrence-free patients over 48 weeks was 46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo (P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1% respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one diverticulitis episode in the year prior to study entry had a lower recurrence risk compared to >1 episode. Safety data revealed no new adverse events. Conclusion: Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.en
dc.description.statusPeer reviewed
dc.format.extent10
dc.format.extent465389
dc.identifier.citationKruis, W, Kardalinos, V, Eisenbach, T, Lukas, M, Vich, T, Bunganic, I, Pokrotnieks, J, Derova, J, Kondrackiene, J, Safadi, R, Tuculanu, D, Tulassay, Z, Banai, J, Curtin, A, Dorofeyev, A E, Zakko, S F, Ferreira, N, Björck, S, Diez Alonso, M M, Mäkelä, J, Talley, N J, Dilger, K, Greinwald, R, Mohrbacher, R & Spiller, R 2017, 'Randomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrence', Alimentary Pharmacology and Therapeutics, vol. 46, no. 3, pp. 282-291. https://doi.org/10.1111/apt.14152
dc.identifier.doi10.1111/apt.14152
dc.identifier.issn0269-2813
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7037
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85019564492&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3.1 Basic medicine
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectHepatology
dc.subjectGastroenterology
dc.subjectPharmacology (medical)
dc.titleRandomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrenceen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Randomised_clinical_trial.pdf
Size:
454.48 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure